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Steroid-dependent nephrotic syndrome in children: Ilistopatho-
logy and relapses after treatment with cyclophosphamide. Chil-
dren with steroid-dependent frequently relapsing nephrotic syn-
drome are generally assumed to have a minimal change in histol-
ogy and therefore to respond favorably to treatment with
cyclophosphamide. The clinical course of 38 children with ste-
roid-sensitive frequently relapsing nephrotic syndrome was ana-
lyzed. Biopsy samples were obtained from these children several
years (mean 6 years) after the onset of their disease but before
they were treated with cyclophosphamide. Three histologic
types of lesions were found: minimal change lesion, 18 patients
(47%); focal and segmental glomerulosclerosis, 11 patients
(29%); and mesangial proliferation, 9 patients (24%). Each pa-
tient then received cyclophosphamide (2 mg/kg of body wt per
day) for 12 weeks, and each responded with a complete remis-
sion, which lasted 1.5 0.2 years. During 6 years of followup
after cyclophosphamide, 17 patients experienced one or more re-
lapses, but 21 patients remained in sustained remission. The in-
cidence of relapse after cyclophosphamide was significantly
greater (P < 0.01) in the patients with focal and segmental gb-
merulosclerosis (8/11, 73%) and mesangial proliferation (5/9,
56%), as compared with children with minimal change lesion (4/
18, 22%). These data indicate that children with frequently
relapsing steroid-dependent nephrotic syndrome (1) will not
all develop minimal-change lesions within several years; in
fact, approximately half will have either focal and segmental
glomerulosclerosis or mesangial proliferation; and (2) after
cyclophosphamide treatment, the incidence of relapse will be re-
lated to the histopathologic type of lesion present at the time of
treatment with cyclophosphämide.
Syndrome néphrotique dépendant des stéroides chez l'enfant:
Histopathologie et récidives aprés cyclophosphamide. II est habit-
uellement postul que les enfants atteints de syndrome nphro-
tique cortico-dëpendant a rechutes multiples n'ont que des l-
sions histologiques minimes et rpondent favorablement au cy-
clophosphamide. L'volution de 38 enfants ayant ce syndrome a
analyse. Ces enfants ont subi des biopsies plusieurs annes
(6 en moyenne) aprds le de1ut de Ia maladie mais avant le traite-
ment par le cyclophosphamide. Trois lsions histologiques ont
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observes: des lesions minimes chez 18 malades (47%), une
glomerulosclerose segmentaire et focale chez 11 malades (29%)
et des prolifCrations mesangiales chez 9 malades (24%). Chaque
malade a recu du cyclophosphamide (2 mg/kg/jour) pendant 12
semaines et tous ont repondu par une remission complete qui a
duré 1,5 0,02 ans. Au cours des 6 années de surveillance
apres cyclophosphamide, 17 malades ont eu une ou plusieurs
rechutes alors que 21 malades restaient en remission. La frC-
quence des rechutes aprés cyclophosphamide a signifi-
cativement plus grande (P < 0,01) chez les malades ayant une
glomerulosclerose segmentaire et focale (8/11, 73%) ou une pro-
liferation mesangiale (5/9, 56%) par comparaison avec les en-
fants n'ayant que des lesions minimes (4/18, 22%). Ces resultats
indiquent: (1) les enfants qui ont un syndrome nephrotique a
rechutes frequentes cortico-dependant n'ont pas tous des lesions
minimes aprés plusieurs annCes d'evolution; en fait, Ia moitié
environ ont soit une glomerulosclérose segmentaire et focale,
soit une proliferation mesangiale; (2) aprCs cyclophosphamide,
Ia frequence des rechutes est en rapport avec Ia lesion histolo-
gique prdsente au moment de l'institution du cyclophosphamide.
Based on their clinical course, children with fre-
quently relapsing steroid-dependent nephrotic syn-
drome are usually assumed to have minimal
changes on renal histologic examination. Con-
sequently, these children may not be subjected to a
renal biopsy before immunosuppressive agents are
added to their steroid therapy [1—5]. Alternatively,
if a biopsy examination is done at the onset of dis-
ease, a second renal biopsy is not usually obtained
at the time of treatment with immunosuppressive
agents, which may be many years later [6-10]. Al-
though the spectrum and distribution of renal le-
sions at the onset of childhood nephrotic syndrome
has been well defined [11-131, the histopathologic
types of lesions that are present at the time immu-
nosuppressive drug therapy is begun in these chil-
dren are not well defined.
Controlled clinical trials have shown that cyclo-
phosphamide [1, 7, 9, 14] and chlorambucil [5] in
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combination with corticosteroids decrease the rate
of relapses in children with steroid-sensitive neph-
rotic syndrome. Relapses after cyclophosphamide
therapy have been associated with a variety of fac-
tors [2, 10, 15], but the relationship between the his-
topathologic type of lesion at the time of initiation
of cytotoxic agents and the subsequent clinical
course has not been delineated. This study of chil-
dren with steroid-dependent frequently relapsing
nephrotic syndrome was designed to determine: (1)
the histopathologic types of lesions that are present
at the time cyclophosphamide therapy is begun, and
(2) the relationship of each of the renal lesions to the
clinical course after the cyclophosphamide-induced
remission.
Methods
Definitions. A remission is defined as the com-
plete absence of proteinuria and edema for at least 1
month, and a relapse is defined as the recurrence of
proteinuria (3 + to 4 + on qualitative testing) on at
least 4 consecutive days after the urine is protein-
free for 1 month. The clinical course is classified as
it relates to steroid treatment (1) steroid responsive,
a complete remission within 8 weeks of prednisone
therapy ( 2 to 3 mg/kg of body wt per day) persisting
for a minimum of 2 months after termination of
treatment; (2) steroid-dependent, frequently-relaps-
ing, a complete remission within 8 weeks of predni-
sone therapy with proteinuria recurring when the
dose is reduced below a critical level, or with a re-
lapse within 2 months after termination of treatment
on at least two successive occasions; and (3) steroid
resistant, no remission after a minimum of 8 con-
secutive weeks of prednisone therapy (2 to 3 mg/kg'
day). Initiation of immunosuppressive therapy is
defined as the time at which cyclophosphamide
therapy is begun.
Patients. Children with the insidious onset of the
nephrotic syndrome, defined as the presence of
heavy proteinuria, hypoalbuminemia (serum albu-
min < 2.5 g/dl), and edema were studied. There
was no evidence of any known cause of the neph-
rotic syndrome. Criteria for selection of patients
were: (1) a steroid-dependent, frequently relapsing
clinical course, (2) a renal biopsy performed imme-
diately prior to initiation of cyclophosphamide ther-
apy, and (3) a complete remission during a 12-week
course of cyclophosphamide.
The 38 children studied represent all the patients
who met the criteria for selection and had been
evaluated by the Renal Division of the Departments
of Pediatrics and Medicine at Yale University
School of Medicine. Only two patients were ex-
cluded from this study because of a failure to re-
spond to cyclophosphamide. All patients were man-
aged with prednisone as previously described [16].
The initial episode of nephrotic syndrome was
treated with prednisone (2 to 3 mg/kg/day) until the
urine was free of protein for 2 to 3 weeks. The dose
of prednisone was then tapered over a 2-week peri-
od and discontinued. Each relapse was treated in a
similar manner as long as the patient remained in
the steroid-responsive category. Once the patient
developed a steroid-dependent frequently relapsing
clinical pattern, a trial of low-dose maintenance
therapy was attempted with prednisone in a maxi-
mum dose of 0.5 mg/kg/day or 1.0 mg/kg on alter-
nate days. Steroid-induced side effects that led to
the use of cyclophosphamide included: psycho-
social or cosmetic problems, 17 patients; impaired
growth or delayed sexual maturation, 14 patients;
cataracts, 3 patients; chronic indolent infection, 2
patients; gastrointestinal bleeding, 1 patient; and
pulmonary embolus, 1 patient. In each case, the ad-
verse side effects of steroid therapy were carefully
considered and were felt to be sufficient to warrant
exposing the patient to the hazards and risks of cy-
clophosphamide therapy. Immediately prior to initi-
ation of immunosuppressive treatment, and after in-
formed consent had been obtained, all patients un-
derwent a percutaneous renal biopsy. They were
then given a 12-week course of cyclophosphamide
(1.5 to 2 mg/kg/day). Prednisone was continued on-
ly during the first 6 weeks of cyclophosphamide
therapy. All relapses that occurred after the 12-
week course of cyclophosphamide were treated
with prednisone alone.
In January 1979, the clinical course and final out-
come of each patient was analyzed. The clinical
status at the end of followup was characterized by
determining BUN, serum creatinine, 24-hour uri-
nary protein excretion, number of relapses after the
course of cyclophosphamide, and current medica-
tions.
Pathology. Renal tissue was evaluated by light
and electron microscopy, without prior knowledge
of the patients' clinical course. For light micros-
copy, sections to 2 to 4 p. in thickness containing at
least six glomeruli were stained with hematoxylin
and eosin, Mallory trichrome and silver methena-
mine. For electron microscopy, portions of each
biopsy were fixed in buffered 3.5% gluteraldehyde
and then processed for ultrastructural examination
as previously described [17]. Histopathologic types
of lesions were identified by the criteria established
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by the International Study of Kidney Disease in
Children and conform to the types of lesions pre-
viously described from our laboratory [18-20]. Min-
ima/-change lesion. There was a conspicuous ab-
sence of abnormality by light microscopy. An occa-
sional region of glomerular mesangial prominence
was not of sufficient degree to warrant either the
term "sclerosis" or proliferation. On ultrastructural
examination, there was extensive obliteration of
epithelial cell foot process, involving all portions of
all glomeruli. There was no evidence of sclerosis,
capillary collapse, or focal tubular atrophy. Mesan-
gui/proliferation. On light microscopy, there was a
slight but definite increase in mesangial cellularity,
the capillary loops were widely patent, and there
was no evidence of epithelial proliferation or adhe-
sions. On electron microscopy, the ultrastructural
appearance of the epithelial cells showed oblitera-
tion of the foot processes. There was an increased
number of mesangial cells and, in some instances,
electron-dense deposits were noted in the mesa-
ngium. Focal and segmental glomerular sclerosis.
Focal and segmental areas of glomerular sclerosis
were present on light microscopy. In some cases,
the fully developed picture included normal. seg-
mentally involved, and completely hyalinized
glomenili. The glomerular changes were accom-
panied by focal areas of tubular atrophy and inter-
stitial scarring. In other instances, the sclerotic lob-
ule was locally adherent to Bowman's capsule and
occasionally had a slight increase in mesangial cells,
but the capillary loops were not patent. On electron
microscopy, there was obliteration of the epithelial
cell foot process, increased mesangial matrix mate-
rial, capsular adhesions, and sclerosis.
Statistical analysis. Data from groups of patients
are given as the means SEM. Proportional changes
between groups were compared by Fisher's exact
test, and differences between groups were deter-
mined by analysis of variance.
Results
Thirty-eight children with steroid-dependent fre-
quently relapsing nephrotic syndrome form the
basis of this report. None of the patients had evi-
dence of azotemia, hematuria, or hypertension at
the onset of disease. Twenty-eight patients were
male, ten were female, and the age at onset of dis-
ease was 4.8 1.2 years with a range of 1 to 17
years. All of the children had a complete remission
of the initial episode of nephrotic syndrome while
on prednisone therapy but followed a steroid-de-
pendent frequently relapsing course. Immuno-
suppressive treatment with cyclophosphamide was
initiated because of steroid-associated side effects
previously noted.
Three histopathologic types of lesions were found
on renal biopsy. Eighteen patients (47%) had mini-
mal-change lesions, whereas nine patients (24%)
had mesangial proliferative lesions and eleven pa-
tients (29%) had focal and segmental glomeruloscle-
rosis. Thus, only half the children studied had mini-
mal glomerular changes on renal biopsy at the time
of initiation of cyclophosphamide therapy, which
averaged 6 years after the onset of disease.
The clinical features of these 38 children prior to
renal biopsy and initiation of cyclophosphamide are
shown in Table 1, grouped according to histopatho-
logic type of lesions. The group of children with
minimal-change lesion consists of 16 males and 2
females, whereas 4 males and 5 females had mesan-
gial-proliferative lesions and 8 males and 3 females
had focal and segmental-glomerulosclerosis lesions.
The patients with focal and segmental glomeru-
losclerosis tended to be a little older (P = 0.05) and
had had their disease for a slightly longer period of
time (0.01 < P < 0.05) compared with the other
groups of children. Otherwise, the clinical features
of the groups were quite similar prior to renal
biopsy and initiation of cyclophosphamide.
Each of the patients responded to cyclophospha-
mide with a complete remission. After the 12-week
course of cyclophosphamide, 21 patients remained
in sustained remission, but 17 patients experienced
one or more relapses. The duration of followup af-
ter cessation of cyclophosphamide was similar in
each of the groups of patients (Table 2). Thus, a
comparison of the clinical course after cyclophos-
phamide between the groups of patients was fea-
sible. The mean duration of the cyclophosphamide-
Table 1. Characteristics of patients prior to biopsy and cyclophosphamide
No. of
patients
Age at onset
of disease
yr
Duration of
disease prior to
cyclophosphamide
yr
Age at biopsy
and initiation of
cyclophosphamide
yr
Relapse rate
per year
Minimalchangelesion
Mesangial proliferative lesion
Focal and segmentalglomeruloscierosis
18
9
11
4.7 0.9
5.5 1.8
4.2 1.3
5.5 1.0
3.8 1.1
9.2 1.6
10.1 1.0
9.2 1.7
13.3 1.1
3.9 0.4
3.8 0.4
3.8 0.4
All values are the means SEM.
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Table 2. Characteristics of patients after cyclophosphamide
Sustained One or more
remission relapses Percent Followup after
no. of no. of with cyclophosphamidea
patients patients relapses yr
Minimal-change lesion 14 4 22 5.7 0.6
Mesangial-proliferative 4 5 56h 4.3 0.7
lesion
Focal- and segmental- 3 8 73' 5.5 0.6
glomerulosclerosis lesion
Values are the means SEM.
b P < 0.01. compared with minimal-change lesion.
induced remission was similar in each group: 1.0
0.4 years in the patients with minimal-change le-
sion, 1.6 0.8 years for the mesangial-proliferative
group, and 1.7 0.5 years for the children with fo-
cal and segmental glomeruloscierosis. The propor-
tion of patients who relapsed after cyclophospha-
mide was, however, significantly greater in the
group with mesangial proliferative lesions (56%, P
<0.01) and in the group with focal and segmental
glomerulosclerosis (73%, P < 0.01) as compared
with the children with minimal-change lesions
(22%) (Table 2).
Among the children who relapsed after cyclo-
phosphamide, the rate of recurrent episodes of
nephrotic syndrome was dramatically reduced:
minimal-change lesion, 0.9 0.5 relapses/year;
mesangial proliferative lesion, 1.1 0.4 relapses!
year; focal and segmental glomeruloscierosis, 0.8
0.2 relapses/year; as compared with the more than
three relapses/year prior to cyclophosphamide.
Thus, treatment with this agent produced a pro-
longed interval of remission and altered the sub-
sequent rate of relapses in each group of patients
irrespective of the histopathologic type of lesion.
At the end of the study period, the total duration
of followup was not significantly different between
the groups and averaged 11.3 1.9 years. All of the
patients continued to be normotensive, had normal
renal function, and were without evidence of sys-
temic disease.
Discussion
The spectrum of histopathologic lesions that
are seen in children at the onset of idiopathic ne-
phrotic syndrome is well established. More than
70% of these children will have minimal glomerular
changes on renal biopsy [11-13]. Children with min-
imal-lesion nephrotic syndrome are typically steroid
responsive and characteristically have a relapsing
clinical course [11—13]. Approximately 30 to 40% of
these children will eventually develop frequently-
relapsing steroid-dependent disease [13, 16]. In
fact, based on their clinical course, children with
frequently relapsing steroid-dependent nephrotic
syndrome are usually thought to have minimal-
change renal histology. Yet, more recent studies
have shown that children with mesangial prolifera-
tive lesions [11, 12, 18, 20, 21] or focal and segmen-
tal glomerulosclerosis [19, 22—25] may also have
steroid-sensitive relapses of their nephrotic syn-
drome. Consequently, the present study was de-
signed to determine the type of renal lesions that
would occur in a group of children with frequently-
relapsing steroid-dependent nephrotic syndrome.
When the renal biopsy was performed immediately
prior to the initiation of cyclophosphamide, which
was several years after the onset of disease, we
found that only 47% of children had minimal gb-
merular changes, but 24% had a mesangial prolifer-
ative lesion and 29% had focal and segmental gb-
menilosclerosis. Because none of these patients un-
derwent a biopsy examination at the onset of
disease, we can not determine if the mesangial pro-
liferative and focal sclerotic lesions represent a
transition from an earlier minimal glomerular lesion
[25] or if they represent the lesion that was present
throughout the clinical course of the patients. Based
on previous observations in patients undergoing
biopsy examination at the onset of disease, it seems
unlikely that the children with focal and segmental
glomeruloscierosis had had that lesion throughout
the course of their disease [25].
The efficacy of cyclophosphamide in the treat-
ment of steroid-dependent frequently-relapsing
nephrotic syndrome has been documented in sever-
al controlled clinical trials [1, 7, 9, 14]. It is also
known that 30 to 50% of children who achieve a re-
mission on cyclophosphamide will subsequently ex-
perience one or more relapses [2, 6-8]. A number of
factors have been proposed as predictors of re-
lapses after cyclophosphamide-induced remission
[2, 10, 15]. The present study was designed to deter-
mine the relationship between the type of histo-
pathologic lesion that was present at the time of mi-
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tiation of immunosuppressive therapy and the clini-
cal course after cyclophosphamide treatment.
During an equivalent period of followup, the pro-
portion of patients who relapsed after treatment
with cyclophosphamide was significantly greater in
the patients with mesangial proliferation or focal
and segmental glomerulosclerosis as compared with
the children with minimal-change lesion. It is im-
portant to point out that the patients with focal and
segmental glomeruloscierosis were older and had
had their disease for a longer time than either of the
other groups (Table 1). Based on the studies of Chiu
and Drummond [2] and McDonald, Murphey, and
Arneil [15], these factors would favor a reduced in-
cidence of relapses in the patients with focal and
segmental glomerulosclerosis, yet almost three
quarters of the patients in this group experienced
one or more relapses. The differences between our
findings and previous observations may be account-
ed for by the selection of patients for study, the time
of renal biopsy relative to initiation of immuno-
suppressive therapy and/or different treatment pro-
tocols. Although Garin et al [10] have proposed that
patients who are steroid-responsive will have a bet-
ter effect from cyclophosphamide than steroid-de-
pendent patients, all of the patients in the present
study had a similar clinical course prior to initiation
of cyclophosphamide. Thus, the incidence of re-
lapse after cyclophosphamide treatment in our pa-
tients with frequently relapsing steroid-dependent
nephrotic syndrome was clearly related to the type
of histopathologic lesion that was present at the
time of initiation of the cytotoxic agent.
Despite the fact that children with mesangial pro-
liferative lesions and those with focal and segmental
glomerular sclerosis had an increased incidence of
relapses after cyclophosphamide, all of the patients
derived benefit from their course of treatment. Each
child achieved a prolonged remission after cessa-
tion of cyclophosphamide, which allowed them to
be free of steroid treatment for more than 1 year
and, thereby, to lose Cushinoid features, to in-
crease growth, and to develop secondary sexual
maturation. Moreover, the patients who relapsed
after cyclophosphamide treatment had a marked re-
duction in the rate of relapses. The International
Study of Kidney Disease in Children has also ob-
served that the rate of subsequent relapse was
lower in frequent relapsers who received cyclo-
phosphamide than in those treated exclusively with
prednisone [9]. None of the patients in the present
study developed any serious side effects from cy-
clophosphamide; only four patients developed tran-
sient leukopenia and six patients had mild thinning
of hair without significant alopecia. No other side
effects of cyclophosphamide were clinically appar-
ent. Nonetheless, the beneficial effects of this drug
must be carefully considered in relation to its poten-
tial toxicity [26-28]. This study was not designed to
encourage the use of cyclophosphamide in children
with relapsing nephrotic syndrome, but rather to
provide important information with regard to the
long-term expectation for children with cyclophos-
phamide-induced remission. Our findings provide
data that should be considered as part of the assess-
ment of the efficacy of cyclophosphamide therapy
for a child with frequently relapsing steroid-depen-
dent nephrotic syndrome.
The present study provides insight into several
aspects of childhood nephrotic syndrome. These
data indicate that when children with frequently re-
lapsing steroid-dependent nephrotic syndrome un-
dergo biopsy examination after several years of dis-
ease: (1) not all children will have minimal change
histology, in fact, approximately one half will have
either a mesangial proliferative lesion or focal and
segmental glomerulosclerosis, and (2) The in-
cidence of relapse after a course of cyclophospha-
mide will be related to the histopathologic type of
lesion that is present at the time of initiation of this
cytotoxic drug.
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